Efficacy and Safety of Xeligekimab in the Treatment of Non-Radiographic Axial Spondyloarthritis (clinicaltrials.gov) - Jan 15, 2026 - P2/3 | N=40 | Not yet recruiting | Sponsor: Lingli Dong
New P2/3 trial • Ankylosing Spondylitis • Immunology • Seronegative Spondyloarthropathies • Spondylarthritis • CRP
|